Clinical Trial Update: Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial investigates genotype-directed dosing of irinotecan within a FOLFIRI plus bevacizumab regimen for metastatic colorectal cancer. The study res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Camptosar (irinotecan)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Colon Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-05-18